Press Releases
April 2, 2024
Upstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership Team
March 7, 2024
Upstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First Patients
October 24, 2023
Upstream Bio Announces Positive Phase 1b Interim Data in Asthma and Company Progress Toward Phase 2
June 8, 2023 Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases
February 7, 2023 Upstream Bio Announces the Appointment of Marcella Ruddy, M.D., to the Board of Directors
October 10, 2022 Upstream Bio Announces Clinical Advisory and Leadership Appointments
August 9, 2022 Upstream Bio Announces Dosing of First Patient in a Phase 1b Clinical Trial of UPB-101 in Asthma
In The News
November 28, 2023
BioSpace: Upstream Bio’s Quest for Effective Best-in-Class Treatments for Allergic Inflammation
June 8, 2023
BioPharma Dive: Upstream Bio raises $200M in fresh funding for asthma drug
June 8, 2023
BioSpace: Upstream Bio Adds Another $200M for Asthma, Allergy Pipeline
June 8, 2023
Endpoints News: Upstream Bio matches first funding round with another $200M to get asthma drug to PhIII
June 8, 2023
Timmerman Report: Startup Profiles: Upstream Bio Gets Another $200M, Kate Therapeutics Debuts With $51M
January 4, 2023
BioSpace: Top Life Sciences Startups to Watch in 2023
September 26, 2022
Timmerman Report: Going Upstream Against Inflammation: Samantha Truex on The Long Run
June 6, 2022
BioCentury: Upstream Bio targeting asthma heterogeneity with $200M
June 2, 2022
BioPharma Dive: Upstream Bio, a richly funded startup, reveals its lead drug and research plans
June 2, 2022
BioSpace: Upstream Bio Dives into Severe Asthma Space with $200M in Series A Financing
June 2, 2022
The Boston Globe: Upstream Bio raises $200m to develop treatment for severe asthma
June 2, 2022
Scrip: Upstream Launches With $200m To Buy, Develop Drugs For Immune-Mediated Diseases